Biotech Venture Funding Tracker 2026
Private financings — Company, date, round, investors, therapeutic area, and a one-line
"what they do."
Last updated:
22 Apr 2026
Unlock the full 2026 VC tracker + get deal alerts
Subscribe (free) to access the full table and get new financings as they land — in
~5 mins/day, read by 2,000+ VC, BD&L, and public biotech investors.
No spam. Unsubscribe anytime.
2026 biotech venture funding snapshot
- 65 venture financings are now tracked in total for 2026 so far.
- Largest disclosed financing so far: Earendil Labs at US$787M disclosed, followed by Parabilis Medicines at US$305M and Beeline Medicines at US$300M.
- The 2026 tape has been broad rather than single-theme, spanning obesity / cardiometabolic, autoimmune / immunology, oncology, CNS / neuropsychiatry, genetic medicines / RNA, ophthalmology, and AI-enabled platforms / biologics.
- A notable read-through is that investors are still funding both late-stage / near-commercial execution stories and next-generation platform or modality bets — from Phase 2/3 and launch-preparation companies to earlier AI, biologics, antibody, RNA, peptide, and cell therapy platforms with clear lead-asset narratives.
April 2026
Tortugas Neuroscience
Seed + Series A
Date:
21-Apr-2026
|
Size:
US$106M
|
Therapeutic area:
Neurology / neuropsychiatry
Investors:
ARCH Venture Partners, NEA, Norwest, PureTech Health, BVF Partners, and Seaport Therapeutics, with additional backing from founding investors Cure Ventures and Lightstone Ventures
What they do:
Neuroscience company launched by former Sage Therapeutics executives with a pipeline of four Phase 2-stage assets licensed from Eisai and Hansoh. The financing supports ongoing development across neuropsychiatry and neurology programs including candidates for major depressive disorder, generalized anxiety disorder, Alzheimer’s disease psychosis, and Parkinson’s disease psychosis.
Ray Therapeutics
Series B
Date:
21-Apr-2026
|
Size:
US$125M
|
Therapeutic area:
Ophthalmology / gene therapy
Investors:
Led by ARCH Venture Partners, with participation from TCGX, Retreat Capital, and existing investors 4BIO Capital, Novo Holdings, and others
What they do:
Clinical-stage biotech developing optogenetic gene therapies for retinal degenerative diseases. Proceeds will advance its vision restoration pipeline, including clinical-stage programs for retinitis pigmentosa and Stargardt disease, while expanding broader retinal development capabilities.
Serif Biomedicines
Launch Financing
Date:
21-Apr-2026
|
Size:
US$50M
|
Therapeutic area:
Genetic medicines / modified DNA therapeutics
Investors:
Flagship Pioneering
What they do:
Flagship-founded biotech building a platform for redosable modified DNA medicines designed to introduce new genetic material into cells without some of the durability and repeat-dosing constraints associated with current genetic medicine approaches.
STORM Therapeutics
Series C
Date:
16-Apr-2026
|
Size:
US$56M
|
Therapeutic area:
Oncology / RNA-modifying enzyme inhibition
Investors:
Existing backers including Pfizer Ventures, M Ventures, Taiho Ventures, IP Group, UTokyo Innovation Platform, and Fast Track Initiative
What they do:
Clinical-stage biotech developing small-molecule modulators of RNA-modifying enzymes for cancer. Proceeds will support the Phase 2 sarcoma study of METTL3 inhibitor STC-15 and broader expansion into additional oncology settings.
Beeline Medicines
Series A
Date:
15-Apr-2026
|
Size:
US$300M
|
Therapeutic area:
Immunology / autoimmune and inflammatory disease
Investors:
Led by Bain Capital
What they do:
Precision immunology company launched with five Bristol Myers Squibb-licensed programs for autoimmune and inflammatory diseases. Lead asset afimetoran, an oral lupus candidate, is expected to complete Phase 2 in 2H 2026, with the financing supporting operations into late-stage clinical development.
Terremoto Biosciences
Series C
Date:
15-Apr-2026
|
Size:
US$108M
|
Therapeutic area:
Oncology / covalent small molecules
Investors:
New investors RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines; participation from existing investors OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management
What they do:
Biotech developing highly targeted covalent small-molecule medicines. Proceeds will advance selective AKT1 inhibitor programs including TER-2013 in oncology and support pipeline expansion into hereditary hemorrhagic telangiectasia.
Neomorph
Series B
Date:
13-Apr-2026
|
Size:
US$100M
|
Therapeutic area:
Oncology / targeted protein degradation
Investors:
Led by Deerfield Management; participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others
What they do:
Clinical-stage biotech developing molecular glue degraders against historically undruggable targets. The financing will support the ongoing Phase 1/2 trial of NEO-811 in locally advanced or metastatic non-resectable clear cell renal cell carcinoma and continued advancement of the broader pipeline.
Vivatides Therapeutics
Series A
Date:
10-Apr-2026
|
Size:
US$54M
|
Therapeutic area:
RNA therapeutics / extrahepatic delivery
Investors:
Co-led by Qiming Venture Partners and a leading industry fund; participation from Highlight Capital, TF Capital, and existing investor Apricot Capital
What they do:
Biotechnology company developing extrahepatic RNA-targeting therapeutics and proprietary delivery technologies designed to move RNA medicines beyond the liver. Proceeds will further advance its delivery platform, accelerate multiple pipeline programs into clinical development, and expand its global team and R&D network.
Oricell Therapeutics
Pre-IPO Financing
Date:
09-Apr-2026
|
Size:
US$110M+
|
Therapeutic area:
Oncology / solid-tumor CAR-T
Investors:
Co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund
What they do:
Global clinical-stage biotechnology company developing cancer immunotherapies, with a focus on solid-tumor CAR-T and in vivo CAR-T technologies. Proceeds will support global development of core assets including Ori-C101, a GPC3-targeted autologous CAR-T therapy for advanced hepatocellular carcinoma, while deepening research into next-generation cell therapy approaches.
Stipple Bio
Series A
Date:
06-Apr-2026
|
Size:
US$100M
|
Therapeutic area:
Oncology / precision biologics
Investors:
Co-led by RA Capital Management, Andreessen Horowitz Bio + Health, and Nextech Invest; participation from existing investors including Emerson Collective Investments (managed by Yosemite), GV, LoLa Capital Partners, and GordonMD Global Investments
What they do:
Precision oncology company emerging from stealth with its Pointillist™ platform, which is designed to drive targeted delivery of potent anti-cancer payloads while widening the therapeutic window. Proceeds will advance lead asset STP-100 into early clinical studies and expand the broader oncology pipeline.
Syneron Bio
Series B
Date:
03-Apr-2026
|
Size:
US$150M
|
Therapeutic area:
Macrocyclic peptides / oncology, autoimmune, metabolic, and rare disease
Investors:
Led by Venrock Healthcare Capital Partners and Goldman Sachs Alternatives; participation from Eli Lilly and Company, Cormorant Asset Management, iCapital funds, Mean Well Ventures, and existing investor Hummingbird Bioscience
What they do:
Macrocyclic peptide company using AI-enabled design and screening to build therapeutics against traditionally hard-to-drug targets. The financing will support advancement of its lead macrocyclic peptide candidates and expansion of a pipeline spanning oncology, autoimmune, metabolic, and rare disease programs.
March 2026
Ambrosia Biosciences
Series B
Date:
31-Mar-2026
|
Size:
US$100M
|
Therapeutic area:
Cardiometabolic / obesity
Investors:
Co-led by Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital; participation from BVF Partners, Boulder Ventures, Janus Henderson Investors, Samsara BioCapital, and an undisclosed institutional investor
What they do:
Biotech developing oral small-molecule cardiometabolic therapies, led by an oral GLP-1 receptor agonist the company says has best-in-class potential. Proceeds will support advancement of the lead oral obesity program and other cardiometabolic assets into clinical development.
Pinnacle Medicines
Series B
Date:
26-Mar-2026
|
Size:
US$89M
|
Therapeutic area:
Oral peptide therapeutics (immunology + cardiometabolic)
Investors:
Co-led by Lilly Asia Ventures (LAV) and Foresite Capital; participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and existing investors including OrbiMed
What they do:
Biotech developing a new generation of oral peptide medicines designed to combine biologic-level efficacy with the convenience of oral dosing. Proceeds will support lead programs through clinical proof of concept, initially focused on immunology and cardiometabolic diseases, and expand its AI- and physics-based peptide discovery platform.
Gilgamesh Pharma
Series A
Date:
24-Mar-2026
|
Size:
US$60M
|
Therapeutic area:
CNS / neuropsychiatry
Investors:
Led by Satori Neuro; participation from new and existing institutional investors including Prime Movers Lab
What they do:
Clinical-stage neuroscience company developing novel therapies for psychiatric and neurological disorders. Lead asset blixeprodil (GM-1020), an oral NMDA receptor antagonist for major depressive disorder, is expected to enter late-stage development in 2026; proceeds also support GM-3009 and broader discovery work.
Immutrin
Series A
Date:
24-Mar-2026
|
Size:
£65M (US$87M)
|
Therapeutic area:
Cardiovascular / amyloidosis
Investors:
Led by Frazier Life Sciences; participation from F-Prime, Qiming Venture Partners, SR One, Cambridge Innovation Capital, and Cambridge Enterprise Ventures
What they do:
UK biotech developing next-generation antibody therapy for ATTR amyloidosis. Proceeds will take its lead antibody asset through clinical proof of concept in ATTR cardiomyopathy, with broader potential across additional amyloidosis indications.
Earendil Labs
Financing Rounds
Date:
20-Mar-2026
|
Size:
US$787M disclosed
|
Therapeutic area:
AI-driven biologics (autoimmune disease, cancer)
Investors:
Dimension Capital, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi, Biotech Development Fund (created by Hillhouse and Pfizer), alongside other new and existing investors
What they do:
AI-native biotech building next-generation antibody and biologics programs. The company said the disclosed financing rounds will scale its R&D platform, expand teams, and advance a pipeline of biologics including HXN-1001, a half-life-extended anti-TL1A antibody ready for Phase 2 development.
Crossbow Therapeutics
Series B
Date:
18-Mar-2026
|
Size:
US$77M
|
Therapeutic area:
Oncology / TCR-mimetic antibodies
Investors:
Co-led by Taiho Ventures and Arkin Bio Capital; participation from Sixty Degree Capital, Hamilton Square Partners, LifeLink Ventures, Libbs Ventures, Blood Cancer United’s Therapy Acceleration Program, and existing investors including MPM BioImpact, Pfizer Ventures, BVF Partners, Polaris Partners, Eli Lilly, and Mirae Asset Venture Investment
What they do:
Oncology company developing TCR-mimetic antibody therapies. Proceeds will support completion of the Phase 1 trial for CBX-250 in myeloid malignancies and advance additional T-Bolt immunotherapies including CBX-663.
R1 Therapeutics
Series A
Date:
17-Mar-2026
|
Size:
US$77.5M
|
Therapeutic area:
Renal / chronic kidney disease
Investors:
Co-led by Abingworth, DaVita Venture Group, and F-Prime; participation from Curie.Bio, SymBiosis, and U.S. Renal Care
What they do:
Clinical-stage biotech focused on kidney disease. Launch financing supports global development of AP306, a pan phosphate transporter inhibitor licensed from Alebund, with a Phase 2b study in hyperphosphatemia planned for later in 2026.
Vima Therapeutics
Series A Extension
Date:
11-Mar-2026
|
Size:
US$40M extension (US$100M Series A total)
|
Therapeutic area:
Neurology / movement disorders
Investors:
New investor Frazier Life Sciences; existing investors Atlas Venture, Access Industries, and Canaan Partners
What they do:
Clinical-stage biotech advancing oral therapies for movement disorders. The extension funds Phase 2 development of VIM0423 in isolated dystonia and Parkinson’s disease, with topline data from both studies expected in 1H 2027.
QL Biopharm
Series C
Date:
02-Mar-2026
|
Size:
US$72M+
|
Therapeutic area:
Metabolic disease / obesity
Investors:
Led by OrbiMed; additional participation from Qiming Venture Partners, 5Y Capital, Apricot Capital, Huagai Capital, with prior investors TF Capital, Lanchi Ventures, and Taiyu Investment continuing to participate
What they do:
Biopharma focused on chronic metabolic diseases. Lead asset zovaglutide (ZT002) is a monthly GLP-1 peptide in Phase 3 for weight loss in China, alongside an oral peptide obesity program and a GLP-1/FGF21 dual agonist pipeline.